913739-02-3

Basic information

• Product Name: 2-(2-ethoxycarbonylbenzothiophen-6-yl)acetic acid
• Synonyms: [2-(ethoxycarbonyl)-1-benzothiophen-6-yl]acetic acid
• CAS NO: 913739-02-3
• Molecular Formula: C₁₃H₁₂O₄S
• Molecular Weight: 264.3
• Mol File: 913739-02-3.mol

Chemical Properties

• Boiling Point: 448.8°C at 760 mmHg
• Flash Point: 225.2°C
• Density: 1.356g/cm³
• Vapor Pressure: 7.67E-09mmHg at 25°C
• Refractive Index: 1.637
• CAS DataBase Reference: 2-(2-ethoxycarbonylbenzothiophen-6-yl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-ethoxycarbonylbenzothiophen-6-yl)acetic acid(913739-02-3)
• EPA Substance Registry System: 2-(2-ethoxycarbonylbenzothiophen-6-yl)acetic acid(913739-02-3)

Safety Data

• Hazardous Substances Data: 913739-02-3(Hazardous Substances Data)

Upstream product

• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 105191-64-8 6-Brombenzothiophen-2-carbonsaeure-ethylester 
• 913738-98-4 di-tert-butyl [2-(ethoxycarbonyl)-1-benzothien-6-yl]malonate 
• 913739-00-1 [2-(ethoxycarbonyl)-1-benzothien-6-yl]malonic acid 

Downstream Products

• 913739-04-5 ethyl 6-(2-anilino-2-oxoethyl)-1-benzothiophene-2-carboxylate 
• 913739-18-1 ethyl 6-{2-[2-(4-methoxybenzoyl)hydrazino]-2-oxoethyl}-1-benzothiophene-2-carboxylate 
• 913739-21-6 6-{[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}-1-benzothiophene-2-carboxylic acid 
• 913739-20-5 ethyl 6-{[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}-1-benzothiophene-2-carboxylate 

Relevant articles and documents

BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES

The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing t

BENZOTHIOPHENE DERIVATIVES

The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.